[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adipokines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adipokines":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":40,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100628121","breastmilk-and-the-link-to-overweightobesity-and-maternal-diet-in-the-mother-breastmilk-child-triad-100628121",false,"NCT07457515","Breastmilk and the Link to Overweight\u002FObesity and Maternal Diet in the Mother-breastmilk-child Triad","Analysis of the Transmission of Overweight\u002FObesity in the Mother-breastmilk-child Triad in Relation to Maternal Cardiometabolic Status and Diet","BLOOM-Triad","Inclusion Criteria:\n\nfor mother:\n\n* at least 19 years,\n* plan of exclusively or predominantly breastfeeding for 6 months,\n* consent to a sampling of biological material and participate in all planned procedures (for both mother and infant),\n* willingness to finish the follow-up,\n* well-understanding of the Polish language (for non-Polish nationalities); for infants:\n* 1 month or less,\n* clinically healthy,\n* none or one formula feeding per day\n\nExclusion Criteria:\n\nfor mother:\n\n* type 1 or 2 diabetes diagnosed before pregnancy,\n* uncontrolled thyroid disease,\n* breastfeeding more than 1 child or being a milk donor,\n* tobacco\u002Falcohol use during pregnancy or currently,\n* inability to express a sufficient amount of milk; for infants:\n* congenital disease,\n* birth from a multiple pregnancy,\n* preterm birth (\\\u003C37 Hbd).",true,"FEMALE","19 Years",{"count":21,"type":22},165,"ESTIMATED","OBSERVATIONAL","The prospective 5-month follow-up study will involve 150 mother-infant dyads grouped based on maternal baseline BMI category (normal weight, overweight, obesity). The investigators plan 3 study visits (1, 3, and 6 months postpartum) with analysis the following parameters and outcomes:\n\n1. maternal anthropometry and body composition;\n2. maternal dietary intake and dietary patterns (with results of biomarker-based validation);\n3. maternal status of lipophilic antioxidants, selected vitamins, and fatty acids profile that may be related to adipose tissue metabolism, inflammation, and cardiometabolic status;\n4. maternal metabolomics, adipokines, insulin, selected biomarkers of inflammation, altered glucose metabolism, and oxidation;\n5. breastmilk composition assessed by systemic approach (macronutrients, fatty acids profile, lipophilic antioxidants, adipokines, hormones, immunological profile, and preliminary lipidomic analysis in part of the study group);\n6. infant growth trajectory, body composition, urine metabolomics, and biomarkers of oxidative stress.\n\nAdditionally, maternal and infant stool, buccal swabs, and human milk samples will be banked for further microbiome analysis studies.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Body Weight","Obesity & Overweight","Human Milk\u002FBreastfeeding","Body Composition","Maternal Cardiometabolic Health","Growth & Development","Metabolomic Profile","Infant Body Composition and Metabolism","Carotenoid Status","Fatty Acid Status","Immunologic Markers","Adipokines","Inflammation Biomarkers","Vitamin E",[41,42,43,44,37,45,46,47,48,49,50,51,52],"Lactation","Body composition","Infant development","Diet","Carotenoids","Fatty acids","Metabolomics","Inflammation","Oxidative stress","Overweight","Obesity","Tocopherols","NOT_YET_RECRUITING","2026-03-02",{"date":56,"type":57},"2026-03-09","ACTUAL",{"date":59,"type":22},"2026-02",{"date":61,"type":22},"2029-09",{"name":63,"class":64},"Warsaw University of Life Sciences","OTHER",4,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":73,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":89,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100583020","impact-of-sarcopenia-on-dyspnea-in-patients-with-asthma-100583020","NCT06870890","Impact of Sarcopenia on Dyspnea in Patients With Asthma","MUDYSA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient affiliated to a social security scheme.\n* Patient capable of giving free, informed, written and signed consent.\n* Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment\n* ACT asthma control score \\\u003C 20\n* Patient judged by the investigator to be able to to perform a maximal exercise test.\n\nExclusion Criteria:\n\n* Patient under guardianship\u002Ftrusteeship\u002Fsupervision of justice\n* Pregnant or breast-feeding women\n* Unstable heart disease\n* Patients who have been smoking or have stopped smoking for less than 5 years,","ALL","18 Years",{"count":76,"type":22},100,"INTERVENTIONAL",[79],"NA","Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.\n\nThe impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .\n\nThe morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.\n\nThe investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.",[82,83,84,85,86,37,87,88],"Sarcopenia","Asthma","Dyspnea","Dyspnea; Asthmatic","Cytokines","Myokine","Muscle Disorder",[83,82,84],"2025-03-10",{"date":92,"type":57},"2025-03-11",{"date":94,"type":22},"2025-03-25",{"date":96,"type":22},"2026-10",{"name":98,"class":64},"University Hospital, Clermont-Ferrand",1]